Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.55 |
| ▸ | F10 | P00742 | 10/20 | 0.51 |
| ▸ | PYGL | P06737 | 7/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3132972 | 0.89 | SMYD3 (0.51) | SMYD3F10PYGLF2PLAT | |
| SCHEMBL10476693 | 0.89 | F10 (0.62) | SMYD3F10PYGLF2PLAT | |
| Hydrochloric Acid SCHEMBL1503926 | 0.88 | F10 (0.62) | SMYD3F10PYGLF2PLAT | |
| Hydrochloric Acid SCHEMBL1503925 | 0.88 | F10 (0.62) | SMYD3F10PYGLF2PLAT | |
| Hydrochloric Acid SCHEMBL2936214 | 0.86 | SMYD3 (0.61) | SMYD3F10PYGLEHMT2 | |
| Hydrochloric Acid SCHEMBL2936213 | 0.86 | SMYD3 (0.61) | SMYD3F10PYGLEHMT2 | |
| Hydrochloric Acid SCHEMBL3335719 | 0.86 | SMYD3 (0.61) | SMYD3F10PYGLEHMT2 | |
| Trifluoroacetic Acid SCHEMBL4093913 | 0.83 | F10 (0.57) | SMYD3F10PYGLF2PLAT | |
| SCHEMBL3143578 | 0.83 | F10 (0.49) | SMYD3F10PYGLF2PLAT | |
| SCHEMBL1855761 | 0.82 | SMYD3 (0.70) | SMYD3F10PYGLEHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344180-B2 | Hydrazine amide derivative | SHIONOGI & CO., LTD. (JP) | 2013-01-01 | — | — | US | claimed |
| US-20100004295-A1 | Hydrazine amide derivative | SHIONOGI & CO., LTD. | 2010-01-07 | — | — | US | claimed |
| EP-2062878-A1 | HYDRAZINE AMIDE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2009-05-27 | — | — | EP | claimed |
| US-8344180-B2 | Hydrazine amide derivative | SHIONOGI & CO., LTD. (JP) | 2013-01-01 | — | — | US | disclosed |
| EP-2062878-A1 | HYDRAZINE AMIDE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2009-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004295-A1 | Hydrazine amide derivative | NPY5R, NPY1R, NPY2R | SMYD3 1907/4885F10 2231/4885PYGL 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.